The effects of phytosomal curcumin supplementation on clinical symptoms, and inflammatory and oxidative stress biomarkers in patients with migraine: A protocol for a randomized double-blind placebo-controlled trial

Document Type : Original Research Article


1 Student Research Committee, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Nutrition and Food Security Research Center and Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. Anesthesia and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran


Objective: Migraine is one of the most common diseases. Curcumin with anti-oxidative and anti-neuroinflammatory properties might have beneficial effects in migraine patients. This study will be conducted to evaluate the effects of a phytosomal preparation of curcumin on clinical signs, oxidative stress, and inflammatory parameters in patients with migraine.
Materials and Methods: This is a randomized, double-blind, placebo-controlled, clinical trial in which, 60 patients with migraine will be assigned to receive a daily dose of 250 mg of phytosomal curcumin for 8 weeks (intervention group) or 250 mg maltodextrin as a placebo for the same duration (control group). Before and after the study, frequency, duration, and severity of the attacks, quality of life and sleep, mood status, high-sensitivity C-reactive protein (hs-CRP), Nitric Oxide (NO), and oxidative stress factors will be measured.
Conclusion: It seems that phytosomal formulation of curcumin (a solid dispersion preparation of curcumin with phosphatidylserine) with high bioavailability, can cross the blood-brain barrier (BBB) and result in decreased neuroinflammation, oxidative stress, and neurotoxicity. This way, phytosomal curcumin might lead to reduction of headaches and other complications of migraine and increase the quality of life of patients with migraine. 


Abdolahi M, Karimi E, Sarraf P, Tafakhori A,
Siri G, Salehinia F, Sedighiyan M,
Asanjarani B, Badeli M, Abdollahi H,
Yoosefi N, Yousefi A, Rad S, Djalali M.
2021. The omega-3 and Nano-curcumin
effects on vascular cell adhesion molecule
(VCAM) in episodic migraine patients: a
randomized clinical trial. BMC Res Notes,
14: 283.
Agosti R. 2018. Migraine burden of disease:
from the patient's experience to a socioeconomic View. Headache, 58 Suppl 1: 17-
Allen SJ, Watson JJ, Shoemark DK, Barua
NU, Patel NK. 2013. GDNF, NGF and
BDNF as therapeutic options for
neurodegeneration. Pharmacol Ther, 138:
Alstadhaug K, Salvesen R, Bekkelund S. 2007.
Insomnia and circadian variation of attacks
in episodic migraine. Headache, 47: 1184-
Atabaki M, Shariati-Sarabi Z, TavakkolAfshari J, Taghipour A, Jafari MR,
Nikpoor AR, Mohammadi M. 2022.
Curcumin as an effective suppressor of
miRNA expression in patients with knee
osteoarthritis. Avicenna J Phytomed, 12:
Mythri RB, Srinivas Bharath MM. 2012.
Curcumin: a potential neuroprotective
agent in Parkinson's disease. Curr Pharm
Des, 18: 91-99.
Bagherniya M, Nobili V, Blesso CN, Sahebkar
A. 2018. Medicinal plants and bioactive
natural compounds in the treatment of nonalcoholic fatty liver disease: A clinical
review. Pharmacol Res, 130: 213-240.
Borkum JM. 2016. Migraine triggers and
oxidative stress: A narrative review and
synthesis. Headache, 56: 12-35.
Borkum JM. 2018. Harnessing migraines for
neural regeneration. Neural Regen Res, 13:
Bruno PP, Carpino F, Carpino G, Zicari A.
2007. An overview on immune system and
migraine. Eur Rev Med Pharmacol Sci, 11:
Bulboacă AE, Bolboacă SD, Bulboacă AC,
Porfire AS, Tefas LR, Suciu SM, Dogaru
G, Stănescu IC. 2019. Liposomal curcumin
enhances the effect of naproxen in a rat
model of migraine. Med Sci Monit, 25:
Bulboacă AE, Bolboacă SD, Stănescu LC,
Sfrângeu CA, Bulboacă AC. 2017.
Preemptive analgesic and antioxidative
effect of curcumin for experimental
migraine. Biomed Res Int, 2017: 4754701.
Chainani-Wu N. 2003. Safety and antiinflammatory activity of curcumin: a
component of tumeric (Curcuma longa). J
Altern Complement Med, 9: 161-168.
Phytosomal curcumin and Migraine
AJP, Vol. 13, No. 1, Jan-Feb 2023 55
Chan A, Tetzlaff WJM, Altman DG, Laupacis
A, Gøtzsche PC, Krleža-Jerić K,
Hróbjartsson A, Mann H, Dickersin K,
Berlin JA, Doré CJ, Parulekar W,
Summerskill WS, Groves KF, Schulz HC,
Sox FW, Rennie RD, Moher D. 2013.
SPIRIT 2013 statement: defining standard
protocol items for clinical trials. Ann Intern
Med, 158: 200-207.
Cole GM, Yang F, Lim GP, Cummings JL,
Masterman DL, Frautschy SA. 2003. A
rationale for curcuminoids for the
prevention or treatment of Alzheimer's
disease. Curr Med Chem Immunol Endocr
Metab Agents, 3: 15-25.
D'Amico D, Tepper SJ. 2008. Prophylaxis of
migraine: general principles and patient
acceptance. Neuropsychiatr Dis Treat, 4:
Economics, Deloitte Access. 2018. Migraine
in Australia whitepaper. Canberra: Deloitte
Access Economics Report. Available in:
Edvinsson L, Haanes KA, Warfvinge K. 2019.
Does inflammation have a role in migraine?
Nat Rev Neurol, 15: 483-490.
Farhadi ZS, Alidoost M, Behzadifar R,
Mohammadibakhsh N, Khodadadi R,
Sepehrian R, Sohrabi M, Taheri Mirghaed
M, Salemi M, Ravaghi H, Behzadifar M.
2016. The prevalence of migraine in Iran:
A systematic review and meta-analysis.
Iran Red Crescent Med J, 18: e40061.
Farhood B, Mortezaee K, Goradel H,
Khanlarkhani N, Salehi E, Nashtaei MS,
Najafi M, Sahebkar A. 2019. Curcumin as
an anti-inflammatory agent: Implications to
radiotherapy and chemotherapy. J Cell
Physiol, 234: 5728-5740.
Farrahi Moghaddam J, Nakhaee N, Sheibani
V, Garrusi B, Amirkafi A. 2012. Reliability
and validity of the Persian version of the
Pittsburgh Sleep Quality Index (PSQI-P).
Sleep Breath, 16: 79-82.
Finocchi C, Sivori G. 2012. Food as trigger
and aggravating factor of migraine. Neurol
Sci, 33: 77-80.
Frautschy SA, Hu W, Kim P, Miller SA, Chu
T, Harris-White ME, Cole GM. 2001.
Phenolic anti-inflammatory antioxidant
reversal of Aβ-induced cognitive deficits
and neuropathology. Neurobiol aging, 22:
Gerring ZF, Powell JE, Montgomery GW,
Nyholt DR. 2018. Genome-wide analysis
of blood gene expression in migraine
implicates immune-inflammatory
pathways. Cephalalgia, 38: 292-303.
Ghasemi SZ, Memarzia A, Behrouz S,
Gholamnezhad Z, Boskabady MH. 2022.
Comparative effects of Curcuma longa and
curcumin on paraquat-induced systemic
and lung oxidative stress and inflammation
in rats. Avicenna J Phytomed, 12: 414-424.
Ghorbani A, Chitsaz A. 2011. Comparison of
validity and reliability of the Migraine
disability assessment (MIDAS) versus
headache impact test (HIT) in an Iranian
population. Iran J Neurol, 10: 39-42.
Glade M, Smith K. 2015. Phosphatidylserine
and the human brain. Nutrition, 31: 781-
Hauge AW, Kirchmann M, Olesen J. 2010.
Trigger factors in migraine with aura.
Cephalalgia, 30: 346-353.
Hewlings SJ, Kalman DS. 2017. Curcumin: A
review of its effects on human health.
Foods, 6: 92.
Hsu CH, Cheng AL. 2007. Clinical studies
with curcumin. Adv Exp Med Biol, 595:
Asha J, Rongqian Wu, Zhou M, Wang P.
2008. Mechanism of the anti-inflammatory
effect of curcumin: PPAR-γ activation.
PPAR Res, 2007: 89369.
Javandoost A, Afshari A, Saberi-Karimian M,
Sahebkar A, Safarian H, Moammeri M,
Fathi Dizaji B, Tavalaei SH, Ferns GA,
Pasdar A. 2018. The effects of curcumin
and a modified curcumin formulation on
serum cholesteryl ester transfer protein
concentrations in patients with metabolic
syndrome: A randomized, placebocontrolled clinical trial. Avicenna J
Phytomed, 8: 330-337.
Jette N, Patten S, Williams J, Becker W,
Wiebe S. 2008. Comorbidity of migraine
and psychiatric disorders--a national
population-based study. Headache, 48:
Karimi L, Crewther SG, Wijeratne T, Evans
AE, Afshari L, Khalil H. 2020. The
prevalence of migraine with anxiety among
genders. Front Neurol, 11: 569405.
Katsarava Z, Mania M, Lampl C, Herberhold
J, Steiner TJ. 2018. Poor medical care for
people with migraine in Europe - evidence
Shojaei et al.
AJP, Vol. 13, No. 1, Jan-Feb 2023 56
from the Eurolight study. J Headache Pain,
19: 10.
Kheiripour N, Khodamoradi Z, Ranjbar A,
Borzouei SH. 2021. The positive effect of
short-term nano-curcumin therapy on
insulin resistance and serum levels of
afamin in patients with metabolic
syndrome. Avicenna J Phytomed, 11: 146-
Kumar Vikas. 2006. Potential medicinal plants
for CNS disorders: an overview. Phytother
Res, 20: 1023-1035.
Kursun O, Yemisci M, Maagdenberg AA,
Karatas H. 2021. Migraine and
neuroinflammation: the inflammasome
perspective. J Headache Pain, 22: 55.
Lantéri-Minet M, Mudge DMG, Cottrell S.
2011. Quality of life impairment, disability
and economic burden associated with
chronic daily headache, focusing on
chronic migraine with or without
medication overuse: a systematic review.
Cephalalgia, 31: 837-850.
Linde M A, Gustavsson LJ, Stovner TJ,
Steiner J, Katsarava BZ, Lainez JM, Lampl
C, Lantéri-Minet M, Rastenyte D, Torre
ER, Tassorelli C, Andrée C. 2012. The cost
of headache disorders in Europe: the
Eurolight project. Eur J Neurol, 19: 703-
Lipton RB, Bigal ME, Diamond M, Freitag F,
Reed ML, Stewart WF. 2007. Migraine
prevalence, disease burden, and the need
for preventive therapy. Neurology, 68: 343-
Lovibond PF, Lovibond SH. 1995. The
structure of negative emotional states:
Comparison of the Depression Anxiety
Stress Scales (DASS) with the Beck
Depression and Anxiety Inventories. Behav
Res Ther, 33: 335-343.
Mayans L, Walling A. 2018. Acute migraine
headache: Treatment strategies. Am Fam
Physician, 97: 243-251.
Mirzaei H, Shakeri A, Rashidi B, Jalili A,
Banikazemi Z, Sahebkar A. 2017.
Phytosomal curcumin: A review of
pharmacokinetic, experimental and clinical
studies. Biomed Pharmacother, 85: 102-
Mohseni M, Sahebkar A, Askari G, Johnston
TP, Alikiaii B, Bagherniya M. 2021. The
clinical use of curcumin on neurological
disorders: An updated systematic review of
clinical trials. Phytother Res, 35: 6862-
Mortezaee K, Salehi E, Mirtavoos-mahyari H,
E. Motevaseli M, Najafi B, Farhood R,
Rosengren J, Sahebkar A. 2019.
Mechanisms of apoptosis modulation by
curcumin: Implications for cancer therapy.
J Cell Physiol, 234: 12537-12550.
Munoz-Ceron J, Marin-Careaga V, Peña L,
Mutis J, Ortiz G. 2019. Headache at the
emergency room: Etiologies, diagnostic
usefulness of the ICHD 3 criteria, red and
green flags. PLoS One, 14: e0208728.
Panahi Y, Ghanei M, Bashiri S, Hajihashemi
A, Sahebkar A. 2014. Short-term
curcuminoid supplementation for chronic
pulmonary complications due to sulfur
mustard intoxication: Positive results of a
randomized double-blind placebocontrolled trial. Drug Res (Stuttg), 65: 567-
Park SY, Darrick SHL. 2002. Discovery of
natural products from Curcuma l onga that
protect cells from beta-amyloid insult: A
drug discovery effort against Alzheimer's
disease. J Nat Prod, 65: 1227-1231.
Parohan M, Sarraf P, Javanbakht MH,
Foroushani AR, Ranji-Burachaloo S,
Djalali M. 2019. The synergistic effects of
nano-curcumin and coenzyme Q10
supplementation in migraine prophylaxis: a
randomized, placebo-controlled, doubleblind trial. Nutr Neurosci, 24: 317-326.
Parsamanesh N, Moossavi M, Bahrami A,
Butler AE, Sahebkar A. 2018. Therapeutic
potential of curcumin in diabetic
complications. Pharmacol Res, 136: 181-
Puledda F, Shields K. 2018. Nonpharmacological approaches for migraine.
Neurotherapeutics, 15: 336-345.
Rezaie S, Askari G, Khorvash F, Tarrahi M,
Amani R. 2021. Effects of curcumin
supplementation on clinical features and
inflammation, in migraine patients: A
double-blind controlled, placebo
randomized clinical trial. Int J Prev Med,
12: 161.
Samani S, Joukar B. 2007. A study on the
reliability and validity of the short form of
the depression anxiety stress scale (DASS21). Shiraz Journal of Social and Human
Sciences, 26: 65-77.
Sareen J, Jacobi F, Cox BJ, Belik SL, Clara I,
Stein MB. 2006. Disability and poor quality
Phytosomal curcumin and Migraine
AJP, Vol. 13, No. 1, Jan-Feb 2023 57
of life associated with comorbid anxiety
disorders and physical conditions. Arch
Intern Med, 166: 2109-2116.
Sedighiyan M, Abdolahi M, Jafari E, Vahabi
Z, Sohrabi Athar S, Hadavi S, Narimani
Zamanabadi M, Yekaninejad MS, Djalali
M. 2022. The effects of nano-curcumin
supplementation on adipokines levels in
obese and overweight patients with
migraine: a double blind clinical trial study.
BMC Res Notes, 15: 189.
Shakeri A, Cicero AFG, Panahi Y, Mohajeri
M, Sahebkar A. 2019. Curcumin: A
naturally occurring autophagy modulator. J
Cell Physiol, 234: 5643-5654.
Sommer C, Kress M. 2004. Recent findings on
how proinflammatory cytokines cause pain:
peripheral mechanisms in inflammatory
and neuropathic hyperalgesia. Neurosci
Lett, 361: 184-187.
Sparreboom A, Cox M, Acharya M, Figg W.
2004. Herbal remedies in the United States:
potential adverse interactions with
anticancer agents. J Clin Oncol, 22: 2489-
Stovner LJ, Nichols E, Steiner TJ, Abd-Allah
F, Abdelalim A, Al-Raddadi RM, Ansha
MG, Barac A, Bensenor IM, Doan LP.
2018. Global, regional, and national burden
of migraine and tension-type headache,
1990–2016: a systematic analysis for the
Global Burden of Disease Study 2016.
Lancet Neurol, 17: 954-976.
Tajti J, Párdutz A, Vámos E, Tuka B, Kuris A,
Bohár Z, Fejes A, Toldi J, Vécsei L. 2011.
Migraine is a neuronal disease. J Neural
Transm (Vienna), 118: 511-524.
Edilia T, Soto V, Ortiz-Vega KM, ZarcoMárquez G, Molina-Jijón E, CristóbalGarcía M, Santamaría J, García-Niño WR,
Correa F, Zazueta C. 2012. Curcumin
induces Nrf2 nuclear translocation and
prevents glomerular hypertension,
hyperfiltration, oxidant stress, and the
decrease in antioxidant enzymes in 5/6
nephrectomized rats. Oxid Med Cell
Longev, 2012: 269039.
Theeler B, Kenney JK, Prokhorenko OA,
Fideli US, Campbell W, Erickson JC. 2010.
Headache triggers in the US military.
Headache, 50: 790-794.
Thiyagarajan M, Sharma SS. 2004.
Neuroprotective effect of curcumin in
middle cerebral artery occlusion induced
focal cerebral ischemia in rats. Life Sci, 74:
Angeliki V, Pavlović JM. 2018. Sleep
disorders and migraine: review of literature
and potential pathophysiology mechanisms.
Headache, 58: 1030-1039.
Yilmaz IA, Ozge A, Erdal ME, Edgünlü TG,
Cakmak SE, Yalin OO. 2010. Cytokine
polymorphism in patients with migraine:
some suggestive clues of migraine and
inflammation. Pain Med, 11: 492-497.
Zandifar A, Masjedi SS, Haghdoost F, Asgari
F, Manouchehri N, Banihashemi M, Najafi
MR, Ghorbani A, Zolfaghari B,
Gholamrezaei A, Shaygannejad V,
Saadatnia M. 2013. The psychometric
properties of the persian migraine-specific
quality of life questionnaire version 2.1 in
episodic and chronic migraines. Sci World
J, 2013: 950245.
Zareie A, Sahebkar A, Khorvash F,
Bagherniya M, Hasanzadeh A, Askari G.
2020. Effect of cinnamon on migraine
attacks and inflammatory markers: A
randomized double-blind placebocontrolled trial. Phytother Res, 34: 2945-
Zhang X , Zhang H, Si L, Li Y. 2011.
Curcumin mediates presenilin-1 activity to
reduce β-amyloid production in a model of
Alzheimer’s disease. Pharmacol Rep, 63: